Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage III Unresectable Non-Small Cell Lung Cancer Clear all
Completed Phase 2 Interventional Results available

Atezolizumab Immunotherapy in Patients With Advanced NSCLC

NCT03102242
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Atezolizumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years to 99 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer

NCT00193453
View directory record Official record
Conditions
Lung Cancer
Interventions
Gemcitabine, Docetaxel, Cetuximab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
10
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT02125461
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MEDI4736, PLACEBO
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
60
States / cities
Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT03132532
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jun 25, 2026, 5:28 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NCT04913285
View directory record Official record
Conditions
Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Interventions
KIN-2787, KIN-2787 and binimetinib
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Active, not recruiting Phase 2 Interventional

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Interventions
RP1, nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Lung Cancer With Copanlisib and Durvalumab

NCT04895579
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Durvalumab, Copanlisib
Drug
Lead sponsor
Zhonglin Hao
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 25, 2026, 5:28 PM EDT
Recruiting Phase 1Phase 2 Interventional

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT05269381
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Endometrial Carcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Skin Squamous Cell Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma, Breast Adenocarcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection, Biopsy, Computed Tomography, Magnetic Resonance Imaging
Drug · Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
16 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Oleclumab, Monalizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
33
States / cities
San Diego, California • New Haven, Connecticut • Stuart, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00075374
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Jun 25, 2026, 5:28 PM EDT
Active, not recruiting Phase 1 Interventional

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

NCT04013542
View directory record Official record
Conditions
ALK Gene Rearrangement, EGFR Gene Mutation, Locally Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Ipilimumab, Nivolumab, Radiation Therapy
Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

NCT00091039
View directory record Official record
Conditions
Lung Cancer
Interventions
recombinant fowlpox GM-CSF vaccine adjuvant, recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

NCT00191139
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
gemcitabine, docetaxel, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
10
States / cities
Denver, Colorado • South Bend, Indiana • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2010 · Synced Jun 25, 2026, 5:28 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

NCT02955290
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 25, 2026, 5:28 PM EDT
Terminated Not applicable Interventional Results available

Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)

NCT00881712
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PET positive nodal disease measuring 15 mm or greater, PET positive nodal disease measuring less than 15 mm, Patients considered resectable
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Early Phase 1 Interventional

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

NCT05873439
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Interventions
Genomically Guided Radiation Therapy (RT)
Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824
View directory record Official record
Conditions
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Interventions
Acasunlimab, Pembrolizumab, Docetaxel
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Vallejo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jun 25, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jun 25, 2026, 5:28 PM EDT
Recruiting Phase 2 Interventional

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Unresectable
Interventions
Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Recruiting Phase 2 Interventional

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

NCT06265285
View directory record Official record
Conditions
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Esophageal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Locally Advanced Urothelial Carcinoma, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Cutaneous Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration
Other · Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Active, not recruiting Phase 1 Interventional

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02495896
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Interventions
Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 25, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

NCT05136846
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Durvalumab, Paclitaxel, Papaverine, Radiation Therapy, Pemetrexed, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging of the Brain with and without Contrast, Biospecimen Collection
Drug · Biological · Radiation + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Duarte, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jun 25, 2026, 5:28 PM EDT